GlassScriptPhysician profile
Bryce Kenneth Galbraith
NPI 1255872560
$4,091.83
in general payments reported to CMS, 2019-2025
37 companies · $1,430 in 2025
The $1,430 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $354 · 2023: $729 · 2024: $1,579 · 2025: $1,430.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,738.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,737.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,175.26 | 2022-2025 | |
| Corcept Therapeutics | $391.11 | 2025 | Korlym |
| Lilly USA, LLC | $258.41 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $244.63 | 2022-2025 | |
| Glaxosmithkline, LLC. | $225.41 | 2024-2025 | Trelegy Ellipta, Arexvy |
| Astellas Pharma US INC | $209.04 | 2023-2025 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $195.81 | 2022-2025 | Xifaxan, Trulance |
| Astrazeneca Pharmaceuticals LP | $178.07 | 2023-2025 | Farxiga, Breztri, Airsupra |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $124.23 | 2025 | Caplyta |
| Dynavax Technologies Corporation | $116.50 | 2022-2025 | Heplisav-B |
| Axsome Therapeutics, INC. | $87.02 | 2024-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $83.01 | 2022-2025 | Spravato |
| Tris Pharma INC | $81.65 | 2025 | Dyanavel Xr |
| Sanofi-Aventis U.S. LLC | $69.59 | 2022-2025 | |
| Idorsia Pharmaceuticals US INC | $69.56 | 2023-2024 | Quviviq |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $50.10 | 2024 | Sublocade |
| Novo Nordisk INC | $48.50 | 2022-2023 | Rybelsus, Ozempic |
| Myriad Genetic Laboratories, INC. | $44.98 | 2024 | Myrisk |
| Inspire Medical Systems, INC. | $44.30 | 2024 | Inspire |
| Biohaven Pharmaceutical Holding Company LTD. | $41.36 | 2022 | |
| Cranial Technologies, INC | $39.11 | 2024-2025 | Doc Band |
| E.R. Squibb & Sons, L.L.C. | $34.55 | 2022 | |
| Merck Sharp & Dohme LLC | $29.23 | 2022-2024 | Gardasil 9, Capvaxive, Rotateq |
| Phathom Pharmaceuticals, INC. | $25.57 | 2024-2025 | Voquezna |
| Organon LLC | $23.77 | 2024-2025 | Nexplanon |
| Neuronetics, INC. | $21.93 | 2025 | Neurostar Tms Therapy System |
| Shield Therapeutics INC | $19.39 | 2024 | |
| Lucid Diagnostics INC. | $18.39 | 2023 | |
| Lundbeck LLC | $18.35 | 2024 | Rexulti |
| Exact Sciences Corporation | $17.87 | 2025 | Cologuard Collection Kit |
| Becton, Dickinson and Company | $17.29 | 2024 | Bd Surepath Collection Vial |
| Bayer Healthcare Pharmaceuticals INC. | $17.24 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.09 | 2023 | Trintellix |
| Sumitomo Pharma America, INC. | $15.00 | 2023 | Gemtesa |
| Treace Medical Concepts, INC. | $13.78 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $13.77 | 2025 | Rexulti |
| Amgen INC. | $12.96 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryce Galbraith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.